HepaCAM induces G1 phase arrest and promotes c-Myc degradation in human renal cell carcinoma.
about
11q deletion in neuroblastoma: a review of biological and clinical implications.Evaluation of the antitumor effects of c-Myc-Max heterodimerization inhibitor 100258-F4 in ovarian cancer cells.A re-emerging marker for prognosis in hepatocellular carcinoma: the add-value of fishing c-myc gene for early relapseNovel agent nitidine chloride induces erythroid differentiation and apoptosis in CML cells through c-Myc-miRNAs axis.The SMAD2/3 pathway is involved in hepaCAM-induced apoptosis by inhibiting the nuclear translocation of SMAD2/3 in bladder cancer cells.Expression of hepaCAM inhibits bladder cancer cell proliferation via a Wnt/β-catenin-dependent pathway in vitro and in vivoHepaCAM associates with connexin 43 and enhances its localization in cellular junctions.Megalencephalic leukoencephalopathy with subcortical cysts protein-1 regulates epidermal growth factor receptor signaling in astrocytes.Overexpression of HepaCAM inhibits cell viability and motility through suppressing nucleus translocation of androgen receptor and ERK signaling in prostate cancer.HepaCAM inhibits clear cell renal carcinoma 786-0 cell proliferation via blocking PKCε translocation from cytoplasm to plasma membrane.Gain of chromosome 8q is associated with metastases and poor survival of patients with clear cell renal cell carcinoma.Overexpression of HepaCAM inhibits bladder cancer cell proliferation and viability through the AKT/FoxO pathway.HepaCAM inhibits the malignant behavior of castration-resistant prostate cancer cells by downregulating Notch signaling and PF-3084014 (a γ-secretase inhibitor) partly reverses the resistance of refractory prostate cancer to docetaxel and enzalutami
P2860
Q32174267-BCBE4C10-A21A-4612-A216-FFE2F4752E1BQ34161727-7D193697-4F8E-4DF9-920E-AA46262A4A1DQ34847309-3A084EBB-DB41-4166-8811-6AF0267AADEAQ35554311-D33F9DF3-4FD6-4152-9C2E-E8766DE224BFQ35922961-4D1C341B-792F-4DBC-AAC2-EA076C159C32Q36839010-6292C627-DB45-444D-8BB2-234D1DE873B5Q37397225-E3DEFF20-403A-477A-B7FF-C2C4DF7F12BDQ38791524-2B05EECC-9EE5-408C-9BF7-EB34E3C9F3CBQ38996973-AE1B259A-6C19-4B11-B15B-D34D2116EE64Q39025188-6B6D3BBE-9211-42DA-9083-0F6537833A57Q46228867-2CC8C417-E201-48C0-8AC7-6214A049623FQ51126611-07C9F015-7531-497D-9592-405CA4674896Q55004240-836AEE6C-0A02-4A85-813C-C40CFCA03561
P2860
HepaCAM induces G1 phase arrest and promotes c-Myc degradation in human renal cell carcinoma.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
HepaCAM induces G1 phase arres ...... in human renal cell carcinoma.
@en
HepaCAM induces G1 phase arres ...... in human renal cell carcinoma.
@nl
type
label
HepaCAM induces G1 phase arres ...... in human renal cell carcinoma.
@en
HepaCAM induces G1 phase arres ...... in human renal cell carcinoma.
@nl
prefLabel
HepaCAM induces G1 phase arres ...... in human renal cell carcinoma.
@en
HepaCAM induces G1 phase arres ...... in human renal cell carcinoma.
@nl
P2093
P2860
P356
P1476
HepaCAM induces G1 phase arres ...... in human renal cell carcinoma.
@en
P2093
Chun-Li Luo
Chun-Yuan Wang
Qiao-Lin Zhang
Sha-Li Shen
Xiao-Hou Wu
Yan-Yi Zhang
P2860
P304
P356
10.1002/JCB.23207
P577
2011-10-01T00:00:00Z